nach oben

Erschienen in:

08.04.2017 | Consensus paper and Guideline

Corticosteroids in the management of acute multiple sclerosis exacerbations

verfasst von: I. Smets, L. Van Deun, C. Bohyn, V. van Pesch, L. Vanopdenbosch, D. Dive, V. Bissay, B. Dubois, On behalf of the Belgian Study Group for Multiple Sclerosis

Erschienen in: Acta Neurologica Belgica | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the central nervous system characterized in the majority of the patients by a relapsing-remitting disease course. For decades high-dosage corticosteroids (CS) are considered the cornerstone in the management of acute MS relapses. However, many unanswered questions remain when it comes to the exact modalities of CS administration. In this review on behalf of the Belgian Study Group for MS we define the efficacy of CS in reducing MS-related morbidity and examine whether the effect is different according to type of CS, route of administration, cumulative dosage, timing of initiation and disease course. We also review the use of CS in combination with other MS treatments and during pregnancy and lactation. Furthermore, we delineate the relevant adverse events due to a pulse CS regimen and present a decision tree that can be used when treating MS relapses in clinical practice.

Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517. doi:10.1016/S0140-6736(08)61620-7 PubMedCrossRef

Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3):606–616. doi:10.1093/brain/awl007 PubMedCrossRef

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133(Pt 7):1914–1929. doi:10.1093/brain/awq118 PubMedPubMedCentralCrossRef

Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. NeuroTherapeutics 4(4):618–626. doi:10.1016/j.nurt.2007.07.008 PubMedCrossRef

Stahn C, Lowenberg M, Hommes DW, Buttgereit F (2007) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275(1–2):71–78. doi:10.1016/j.mce.2007.05.019 PubMedCrossRef

Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11(4):425–432PubMedCrossRef

Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O’Shea JJ, Chrousos GP, Bornstein SR (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16(1):61–71. doi:10.1096/fj.01-0245com PubMedCrossRef

Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60(5):563–572PubMed

Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X (2002) Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 127(1):165–171PubMedPubMedCentralCrossRef

10.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 PubMedPubMedCentralCrossRef

11.

Guthrie TC, Nelson DA (1995) Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 129(1):1–8PubMedCrossRef

12.

D’Hooghe MB, Nagels G, Bissay V, De Keyser J (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 16(7):773–785. doi:10.1177/1352458510367721 PubMedCrossRef

13.

Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67(4):652–659. doi:10.1212/01.wnl.0000233834.09743.3b PubMedCrossRef

14.

Mohr DC, Hart SL, Julian L, Cox D, Pelletier D (2004) Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 328(7442):731. doi:10.1136/bmj.38041.724421.55 PubMedPubMedCentralCrossRef

15.

Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 4:CD001331. doi:10.1002/14651858.CD001331

16.

Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo—final report. Neurology 20(5):1–59PubMed

17.

Brusaferri F, Candelise L (2000) Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247(6):435–442PubMedCrossRef

18.

Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick RA (2000) A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 6(4):267–273PubMedCrossRef

19.

Ramo-Tello C, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Grau-Lopez L (2016) Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Mult Scler 22(1):117–121. doi:10.1177/1352458515590648 PubMedCrossRef

20.

Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588. doi:10.1056/NEJM199202273260901 PubMedCrossRef

21.

Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24):1764–1769. doi:10.1056/NEJM199312093292403 PubMedCrossRef

22.

Goodin DS (1999) Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 18(2):53–63. doi:10.1159/000069408 PubMedCrossRef

23.

Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51(2):529–534PubMedCrossRef

24.

Miller H, Newell DJ, Ridley A (1961) Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 2(7212):1120–1122PubMedCrossRef

25.

Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36(2):238–243PubMedCrossRef

26.

Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50(5):511–516PubMedPubMedCentralCrossRef

27.

Filipovic SR, Drulovic J, Stojsavljevic N, Levic Z (1997) The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J Neurol Sci 152(2):147–153PubMedCrossRef

28.

La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V (1994) Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 34(4):199–203PubMedCrossRef

29.

Milanese C, La Mantia L, Salmaggi A, Campi A, Eoli M, Scaioli V, Nespolo A, Corridori F (1989) Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 29(1):10–14PubMedCrossRef

30.

Tandon R, Verma K, Chawla B, Sharma N, Titiyal JS, Kalaivani M, Vajpayee RB (2009) Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection. Eye 23(3):635–639. doi:10.1038/eye.2008.25 PubMedCrossRef

31.

Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R et al (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39(7):969–971PubMedCrossRef

32.

Burton JM, O’Connor PW, Hohol M, Beyene J (2012) Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 12:CD006921. doi:10.1002/14651858.CD006921.pub3 PubMed

33.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, investigators C, West Network for Excellence in N (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0 PubMedCrossRef

34.

Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, Ramio I, Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalban X, Martinez-Caceres E, Costa J (2014) A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 20(6):717–725. doi:10.1177/1352458513508835 PubMedCrossRef

35.

Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M (2009) A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 73(22):1842–1848. doi:10.1212/WNL.0b013e3181c3fd5b PubMedCrossRef

36.

Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM (2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63(6):1079–1080PubMedCrossRef

37.

Grau-Lopez L, Teniente-Serra A, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Martinez-Caceres EM, Ramo-Tello C (2015) Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses. Mult Scler 21(5):646–650. doi:10.1177/1352458514546786 PubMedCrossRef

38.

Comi G, Radaelli M (2015) Oral corticosteroids for multiple sclerosis relapse. Lancet 386(9997):937–939. doi:10.1016/S0140-6736(15)00072-0 PubMedCrossRef

39.

Kister I, Corboy JR (2016) Reducing costs while enhancing quality of care in MS. Neurology 87(15):1617–1622. doi:10.1212/WNL.0000000000003113 PubMedCrossRef

40.

Alam SM, Kyriakides T, Lawden M, Newman PK (1993) Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 56(11):1219–1220PubMedPubMedCentralCrossRef

41.

Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349(9056):902–906PubMedCrossRef

42.

Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol 15:206. doi:10.1186/s12883-015-0450-x PubMedPubMedCentralCrossRef

43.

Levic Z, Micic D, Nikolic J, Stojisavljevic N, Sokic D, Jankovic S, Kendereski A, Mavra M (1996) Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest 19(1):30–34. doi:10.1007/BF03347855 PubMedCrossRef

44.

Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10(1):89–91PubMedCrossRef

45.

Iuliano G, Napoletano R, Esposito A (2008) Multiple sclerosis: relapses and timing of remissions. Eur Neurol 59(1–2):44–48. doi:10.1159/000109260 PubMed

46.

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TT Group (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256. doi:10.1016/S1474-4422(13)70308-9 PubMedCrossRef

47.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CS Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097. doi:10.1056/NEJMoa1206328 PubMedCrossRef

48.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, Rs group (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the rebif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903–914. doi:10.1016/S1474-4422(08)70200-X PubMedCrossRef

49.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, Clinical and Medical Investigations (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. doi:10.1016/S0140-6736(12)61769-3 PubMedCrossRef

50.

Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801. doi:10.1056/NEJMoa0802670 CrossRef

51.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators A (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910. doi:10.1056/NEJMoa044397 PubMedCrossRef

52.

Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M (2014) Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 20(5):527–536. doi:10.1177/1352458513519840 PubMedPubMedCentralCrossRef

53.

Vukusic S, Marignier R (2015) Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol 11(5):280–289. doi:10.1038/nrneurol.2015.53 PubMedCrossRef

54.

Houtchens MK, Kolb CM (2013) Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 260(5):1202–1214. doi:10.1007/s00415-012-6653-9 PubMedCrossRef

55.

Lyons PR, Newman PK, Saunders M (1988) Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 51(2):285–287PubMedPubMedCentralCrossRef

56.

Carpani de Kaski M, Rentsch R, Levi S, Hodgson HJ (1995) Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut 37(5):613–616PubMedPubMedCentralCrossRef

57.

Guslandi M, Tittobello A (1992) Steroid ulcers: a myth revisited. BMJ 304(6828):655–656PubMedPubMedCentralCrossRef

58.

Poetker DM, Reh DD (2010) A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 43(4):753–768. doi:10.1016/j.otc.2010.04.003 PubMedCrossRef

59.

Warrington TP, Bostwick JM (2006) Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81(10):1361–1367. doi:10.4065/81.10.1361 PubMedCrossRef

60.

McLuckie AE, Savage RW (1993) Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 104(2):622–623PubMedCrossRef

61.

Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G (2000) Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol 7(1):130PubMedCrossRef

62.

Caster O, Conforti A, Viola E, Edwards IR (2014) Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol 70(4):501–503. doi:10.1007/s00228-013-1632-3 PubMedCrossRef

63.

Gutkowski K, Chwist A, Hartleb M (2011) Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature. Hepat Mon 11(8):656–661PubMedPubMedCentralCrossRef

64.

Lopez-Serrano MC, Moreno-Ancillo A, Contreras J, Ortega N, Cabanas R, Barranco P, Munoz-Pereira M (1996) Two cases of specific adverse reactions to systemic corticosteroids. J Investig Allergol Clin Immunol 6(5):324–327PubMed

65.

Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 9(6):600–604PubMedCrossRef

66.

Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12(7):550–556. doi:10.1111/j.1468-1331.2005.00988.x PubMedCrossRef

67.

Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M (2012) Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci 33(6):1443–1446. doi:10.1007/s10072-011-0914-8 PubMedCrossRef

68.

Costedoat-Chalumeau N, Amoura Z, Aymard G, Sevin O, Wechsler B, Cacoub P, Du LT, Diquet B, Ankri A, Piette JC (2000) Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 132(8):631–635PubMedCrossRef

69.

Hazlewood KA, Fugate SE, Harrison DL (2006) Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 40(12):2101–2106. doi:10.1345/aph.1H418 PubMedCrossRef

70.

Varis T, Kivisto KT, Neuvonen PJ (2000) The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 56(1):57–60PubMedCrossRef

71.

Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886PubMedCrossRef

72.

Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases—current guidelines and future perspectives. Atheroscler Suppl 10(5):129–132. doi:10.1016/S1567-5688(09)71827-6 PubMedCrossRef

Titel: Corticosteroids in the management of acute multiple sclerosis exacerbations
verfasst von: I. Smets
L. Van Deun
C. Bohyn
V. van Pesch
L. Vanopdenbosch
D. Dive
V. Bissay
B. Dubois
On behalf of the Belgian Study Group for Multiple Sclerosis
Publikationsdatum: 08.04.2017
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 3/2017
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-017-0772-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Unknown onset ischemic strokes in patients last-seen-well >4.5 h: differences between wake-up and daytime-unwitnessed strokes

The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine

Paraneoplastic rhombencephalitis and cerebellitis preceded by isolated intractable vomiting

Early onset brain calcifications secondary to hypoparathyroidism in a boy with syncopal-like symptomatology

Transient IgG deficiency with lesions in brain and spinal cord: a mimicker of common variable immunodeficiency syndrome